4 results on '"Steegers, Monique A.H."'
Search Results
2. Physicians' Opinions on Anticoagulant Therapy in Patients with a Limited Life Expectancy.
- Author
-
Huisman, Bregje A.A., Geijteman, Eric C.T., Kolf, Nathalie, Dees, Marianne K., van Zuylen, Lia, Szadek, Karolina M., Steegers, Monique A.H., and van der Heide, Agnes
- Subjects
LIFE expectancy ,PHYSICIANS ,QUALITY of life ,ANTICOAGULANTS ,MEDICAL care - Abstract
Patients with a limited life expectancy have an increased risk of thromboembolic and bleeding complications. Anticoagulants are often continued until death, independent of their original indication. We aimed to identify the opinions of physicians about the use of anticoagulants at the end of life. A mixed-method research design was used. A secondary analysis was performed on data from a vignette study and an interview study. Participants included general practitioners and clinical specialists. Physicians varied in their opinions: some would continue and others would stop anticoagulants at the end of life because of the risk of thromboembolic or bleeding complications. The improvement or preservation of patients' quality of life was a reason for both stopping and continuing anticoagulants. Other factors considered in the decision-making were the types of anticoagulant, the indication for which the anticoagulant was prescribed, underlying diseases, and the condition and life expectancy of the patient. Factors that made decision-making difficult were the lack of evidence on either strategy, uncertainty about patients' life expectancy, and the fear of harming patients. Which decision was eventually made seems largely dependent on the choice of the patient. In conclusion, there is a substantial variation in physicians' opinions regarding the use of anticoagulants in patients with a limited life expectancy. Physicians agree that the primary goal of medical care at end of life is the improvement or preservation of patients' quality of life. An important barrier to decision-making is the lack of evidence about the risks and benefits of stopping anticoagulants. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Use of antithrombotics at the end of life: an in-depth chart review study.
- Author
-
Huisman, Bregje A.A., Geijteman, Eric C.T., Arevalo, Jimmy J., Dees, Marianne K., van Zuylen, Lia, Szadek, Karolina M., van der Heide, Agnes, and Steegers, Monique A.H.
- Subjects
THERAPEUTIC use of fibrinolytic agents ,HOSPICE care ,TERMINAL care ,ACQUISITION of data methodology ,TERMINALLY ill ,PATIENTS ,RETROSPECTIVE studies ,QUALITY of life ,MEDICAL records ,CASE studies ,JUDGMENT sampling ,SECONDARY analysis - Abstract
Background: Antithrombotics are frequently prescribed for patients with a limited life expectancy. In the last phase of life, when treatment is primarily focused on optimizing patients' quality of life, the use of antithrombotics should be reconsidered. Methods: We performed a secondary analysis of a retrospective review of 180 medical records of patients who had died of a malignant or non-malignant disease, at home, in a hospice or in a hospital, in the Netherlands. All medication prescriptions and clinical notes of patients using antithrombotics in the last three months of life were reviewed manually. We subsequently developed case vignettes based on a purposive sample, with variation in setting, age, gender, type of medication, and underlying disease. Results: In total 60% (n=108) of patients had used antithrombotics in the last three months of life. Of all patients using antithrombotics 33.3 % died at home, 21.3 % in a hospice and 45.4 % in a hospital. In total, 157 antithrombotic prescriptions were registered; 30 prescriptions of vitamin K antagonists, 60 of heparins, and 66 of platelet aggregation inhibitors. Of 51 patients using heparins, 32 only received a prophylactic dose. In 75.9 % of patients antithrombotics were continued until the last week before death. Case vignettes suggest that inability to swallow, bleeding complications or the dying phase were important factors in making decisions about the use of antithrombotics. Conclusions: Antithrombotics in patients with a life limiting disease are often continued until shortly before death. Clinical guidance may support physicians to reconsider (dis)continuation of antithrombotics and discuss this with the patient. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life.
- Author
-
Haren, Frank G.A.M., Steegers, Monique A.H., Thijssen, Marloes, Wal, Selina E.I., Vissers, Kris C.P., and Engels, Yvonne
- Subjects
- *
PERIPHERAL neuropathy , *RESEARCH methodology , *FUNCTIONAL status , *CANCER chemotherapy , *ACTIVITIES of daily living , *INTERVIEWING , *QUALITATIVE research , *QUALITY of life , *OXALIPLATIN , *JUDGMENT sampling , *DATA analysis software , *THEMATIC analysis , *EMOTIONS , *ACUTE diseases - Abstract
Introduction/Aims: Oxaliplatin often causes acute or chronic peripheral neuropathy in patients with an intestinal or pancreatic tumor, but in‐depth insights in its influence on quality of life (QoL) are lacking. We explored the influence of acute oxaliplatin‐induced peripheral neuropathy (OIPN) on daily QoL in these patients. Methods: We performed semistructured interviews with a purposive sample of patients receiving oxaliplatin and possibly experiencing acute OIPN. Interviews were audio‐recorded, transcribed verbatim, and coded by two researchers. Data were analyzed by using the constant comparative method for content analysis with ATLAS.ti software. Results: After nine patients, saturation took place. In total, 11 patients were interviewed. Four themes were extracted from the data: (1) adverse effects, (2) physical (un)well‐being, (3) emotional aspects, and (4) treatment aspects. All participants were suffering from acute OIPN to a certain extent, leading to restrictions in daily activities such as household chores, but also to a decrease in mobility and independency. Other adverse effects such as general malaise and gastrointestinal side effects also influenced the participants' well‐being, as did the diagnosis and prognosis of their disease. Conclusion: Acute OIPN, together with other side effects of chemotherapeutic treatment and the difficulties that come with the diagnosis of cancer and its prognosis, largely influences patients' daily QoL. Managing expectations (by patient education) seems important. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.